Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17146470 | 0.91 | — | — | |
| SCHEMBL23084093 | 0.82 | DPP4 (0.32) | DPP4 | |
| SCHEMBL23086702 | 0.80 | DPP4 (0.46) | DPP4ALDH1A1 | |
| SCHEMBL21558067 | 0.78 | DPP4 (0.34) | DPP4 | |
| SCHEMBL23086688 | 0.77 | DPP4 (0.36) | DPP4ALDH1A1 | |
| SCHEMBL6201919 | 0.76 | ALDH1A1 (0.36) | DPP4ALDH1A1 | |
| SCHEMBL2292115 | 0.74 | — | — | |
| SCHEMBL19601432 | 0.73 | — | — | |
| SCHEMBL878835 | 0.72 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL11299703 | 0.72 | ALDH1A1 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| EP-3792260-B1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | NIPPON SHINYAKU CO LTD (JP) | 2024-09-11 | — | — | EP | disclosed |
| CN-112368282-B | Azabenzimidazole compounds and medicaments | 日本新药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20230000840-A1 | THERAPEUTIC AGENTS AND PROPHYLACTIC AGENTS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| EP-4059503-A1 | THERAPEUTIC AGENT AND PROPHYLACTIC AGENT FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | Nippon Shinyaku Co., Ltd. (JP) | 2022-09-21 | — | — | EP | disclosed |
| EP-4059933-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2022-09-21 | — | — | EP | disclosed |
| CN-114929697-A | Azabenzimidazole compounds and medicaments | 日本新药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-114901283-A | Therapeutic and prophylactic agent for functional digestive tract disorder and xerostomia | 日本新药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| US-20210371412-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| WO-2021095805-A1 | THERAPEUTIC AGENT AND PROPHYLACTIC AGENT FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | 日本新薬株式会社 | 2021-05-20 | — | — | WO | disclosed |
| WO-2021095801-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | 日本新薬株式会社 | 2021-05-20 | — | — | WO | disclosed |
| EP-3792260-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2021-03-17 | — | — | EP | disclosed |
| CN-112368282-A | Azabenzimidazole compounds and pharmaceuticals | 日本新药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| WO-2019216294-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | 日本新薬株式会社 (JP) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | PAM, CHRM3, AZI2 | DPP4 210/4885HIF1A 4227/4885ALDH1A1 383/4885 |
| US-20210371412-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | PAM, CHRM3, AZI2 | DPP4 419/4885HIF1A 4331/4885ALDH1A1 480/4885 |
| US-20230000840-A1 | THERAPEUTIC AGENTS AND PROPHYLACTIC AGENTS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | ALPI, SI, AZI2 | DPP4 257/4885HIF1A 3842/4885ALDH1A1 1074/4885 |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | PAM, CHRM3, AZI2 | DPP4 419/4885HIF1A 4331/4885ALDH1A1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.